clinical trial · NCT07102940
Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer
George Washington University·phase2·not yet recruiting·n = 50
Breast CancerHER 2 Negative Breast CancerHR Positive/HER-2 Negative Breast CancerStage 1-3Eftilagimod Alfa (Efti)Docetaxel-cyclophosphamide (TC) intravenous (i.v)Dose dense Adriamycin-cyclophosphamide (AC) i.v
brief summary
The goal of this interventional study is to determine pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) and Efti treatment. This is a prospective single arm interventional trial in patients with early-stage HR+/HER2 -ve breast cancer (Stage I-III) who are eligible for neoadjuvant chemotherapy (NAC). Enrolled patients will be treated with single agent efti for 3 weeks and then start NAC in combination with efti. There are 2 standard NAC usually used and will be determined by treating physician prior to starting on this trial.
started
Sep 1, 2026
primary completion
Aug 1, 2028
completion
Aug 1, 2028
last updated
Jun 11, 2026
official title
Eftilagimod Alpha in Combination With Neoadjuvant Chemotherapy in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol